Skip to main content

Table 3 Major adverse events

From: Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis

Event    Cell therapy group Control group Odds ratio
Follow-up Study (participants) Total event Participants Total event Participants (M-H, random) 95 % CI
All-cause mortality 6 mo 18 (1284) 10 707 6 577 1.08 0.42–2.81
1 yr 8 (286) 5 174 4 112 0.89 0.24–3.32
3 yr 5 (432) 9 228 11 204 0.58 0/22–1.56
5 yr 5 (458) 10 226 22 232 0.45 0.21–0.97
Heart failure admission 6 mo 9 (970) 10 512 15 458 0.56 0.24–1.31
1 yr 3 (83) 2 42 0 41 3.07 0.30–30.96
2 yr 4 (333) 4 179 14 154 0.15 0.04–0.50
3 yr 6 (577) 11 284 17 293 0.65 0.30–1.44
Recurrence of ischemic heart disease 6 mo 14 (1214) 29 663 37 551 0.57 0.32–1.00
1 yr 2 (81) 0 48 1 33 0.14 0.01–3.68
2 yr 6 (373) 6 199 11 174 0.68 0.18–2.56
3 yr 6 (528) 9 262 11 266 0.81 0.33–2.00
Revascularization/restenosis 6 mo 14 (1212) 98 662 92 550 0.87 0.63–1.22
1 yr 4 (156) 2 87 4 69 0.37 0.07–1.89
2 yr 6 (373) 36 199 45 174 0.65 0.39–1.10
3 yr 6 (577) 62 284 76 293 0.77 0.52–1.15
Cerebral vascular accident (CVA) 1 yr 2 (150) 1 68 2 82 0.69 0.08–5.81
2 yr 3 (500) 5 248 10 252 0.5 0.16–1.50
  1. M-H Mantel-Haenszel, CI confidence interval, mo months, yr years